SAN DIEGO, Jan. 31 Cadence Pharmaceuticals, Inc.(Nasdaq: CADX), a biopharmaceutical company focused on in-licensing,developing and commercializing proprietary product candidates principally foruse in the hospital setting, announced today that the company's President andCEO Theodore Schroeder will present the corporate overview on Tuesday,February 5, 2008 at 4:00 pm Eastern Time (1:00 pm Pacific Time) during theMerrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conferencein New York City.
The presentation will be simultaneously webcast and can be accessed onCadence Pharmaceuticals' website at http://www.cadencepharm.com in theInvestor Relations section. A replay of the webcast will be availableapproximately three hours following the live webcasts and will be archived for14 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused onin-licensing, developing and commercializing proprietary product candidatesprincipally for use in the hospital setting. The company currently has twoPhase III product candidates in development, Acetavance(TM) (intravenousacetaminophen) for the treatment of acute pain and fever, and Omigard(TM)(omiganan pentahydrochloride 1% topical gel) for the prevention ofcatheter-related infections. For more information about Cadence's pipeline,visit http://www.cadencepharm.com.
Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals,Inc.Contacts: William R. LaRue Anna Gralinska SVP & Chief Financial Officer Director, Investor Relations Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc. 858-436-1400 858-436-1452
SOURCE Cadence Pharmaceuticals, Inc.